2024 15th Annual NUBE Conference

In 2018 , the FDA has granted psilocybin a “ breakthrough therapy designation “ status for treatment- resistant depression. One year later , another “ breakthrough therapy designation” was granted to Psilocybin for treatment of MDD. This designation reflects the drug potential to treat resistant psychiatric disorder. Recent studies reveals that psilocybin assisted therapy offer a wide range of possible therapeutic benefits ( for example in alcohol use disorder , tobacco use disorder and end-of-life anxiety and depression). In this presentation, I will explain what is psilocybin-assisted therapy and what disorders it  help with based on recent studies.

Learning Objectives:

Obtain knowledge on history of psychedelic therapy from the past to the present time.

Discuss psilocybin pharmacology and phases of psilocybin therapy.

Discuss therapeutic benefits of psilocybin based on recent studies.